How should I manage a patient with a reported antibiotic allergy?

Management of Antibiotic Allergy

In patients with reported antibiotic allergy, implement a systematic risk-stratification approach based on reaction type and severity, then use side-chain similarity principles to safely administer alternative beta-lactams without testing in most cases.

Risk Stratification Framework

The first critical step is categorizing the reported allergy by reaction type and severity 1:

Immediate-Type Reactions (IgE-mediated, <1 hour)

• Non-severe: Urticaria, pruritic rash, mild angioedema
• Severe: Anaphylaxis, severe angioedema, bronchospasm

Delayed-Type Reactions (>1 hour to days)

• Non-severe: Maculopapular exanthem, isolated pruritus
• Severe: SCAR (Stevens-Johnson syndrome, TEN, DRESS, AGEP), organ involvement

Low-Risk Histories (Often Not True Allergies)

• Gastrointestinal symptoms alone
• Family history only
• Pruritus without rash
• Remote reactions >10 years ago without IgE features
• Unknown reactions without concerning features 2

Penicillin Allergy Management

For Non-Severe Delayed-Type Penicillin Allergy

You can safely give carbapenems or aztreonam without any prior testing, regardless of when the reaction occurred 1. This is a strong recommendation.

For cephalosporins, use the side-chain similarity rule:

• Avoid cephalexin, cefaclor, and cefamandole (share side chains with amoxicillin/penicillin) 1
• Safe to use all other cephalosporins, including cefazolin, ceftriaxone, cefepime 1

For Non-Severe Immediate-Type Penicillin Allergy

• Carbapenems: Safe without testing (though cross-reactivity is slightly higher than with delayed reactions) 3
• Cephalosporins with dissimilar side chains: Safe to use 1
• Aztreonam: Safe without testing unless ceftazidime allergy 3

For Severe Immediate-Type Reactions (Anaphylaxis)

• Avoid all penicillins 1
• Avoid cephalosporins with similar side chains 1
• Carbapenems: Can be used (cross-reactivity <1%) but consider graded challenge in anxious patients 3
• Aztreonam: Safe without testing 3

For Severe Delayed-Type Reactions (SCAR)

Avoid all beta-lactam antibiotics 1. This is the only scenario requiring complete beta-lactam avoidance.

Cephalosporin Allergy Management

Cross-reactivity between cephalosporins is R1 side-chain dependent, not class-based 1:

For Cefazolin Allergy

• Safe: All penicillins and other cephalosporins (cefazolin is a selective allergy) 1

For Ceftazidime/Cefiderocol Allergy

• Avoid aztreonam (shares identical side chain) 1
• Safe: All penicillins and other cephalosporins 1

For Other Cephalosporin Allergies

• Safe: Penicillins with dissimilar side chains 1
• Safe: Other cephalosporins with dissimilar side chains 1

Carbapenem and Aztreonam Allergy

For Carbapenem Allergy

• Cephalosporins can be given in a monitored clinical setting 1
• Penicillins can be given in a monitored clinical setting if no penicillin allergy history 1

For Aztreonam Allergy

• Avoid ceftazidime and cefiderocol only 1
• Safe: All other cephalosporins and all penicillins 1

Implementation Strategy

Collaborate with antimicrobial stewardship programs to implement beta-lactam allergy pathways 3. These pathways should include:

1. Electronic health record triggers for allergy assessment 3
2. History-based risk stratification at point of prescribing 3
3. Direct drug challenges for low-risk patients (>90% will tolerate) 2, 4
4. Allergy testing referral for moderate-risk patients 3

Critical Pitfalls to Avoid

• Don't assume class-based cross-reactivity: The old "10% cross-reactivity" between penicillins and cephalosporins is outdated; actual rate is 2-3% and side-chain dependent 2, 5
• Don't use broad-spectrum alternatives unnecessarily: This increases MRSA, VRE, C. difficile risk, surgical site infections, and healthcare costs 2, 5
• Don't forget that IgE-mediated allergy wanes: 80% of patients lose reactivity after 10 years 2
• Don't overlook mislabeling: >90% of reported penicillin allergies are not true allergies 2, 4

When Formal Allergy Evaluation Is Needed

Refer for skin testing and/or oral challenge when:

• Moderate-risk history (urticaria, features of IgE reaction) 2
• Need for definitive delabeling 3
• Multiple drug allergies 3
• Significant patient anxiety 3

For sulfonamide antibiotic allergies with benign cutaneous reactions >5 years ago, perform a 1-step drug challenge with TMP-SMX when delabeling is needed 3.